|
|
| | 4-(4-Benzhydryl-1-piperazinyl)-1-methyl-3-nitroquinolin-2(1H)-one Basic information |
| | 4-(4-Benzhydryl-1-piperazinyl)-1-methyl-3-nitroquinolin-2(1H)-one Chemical Properties |
| Boiling point | 551.877±50.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.340±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 5.635±0.70(predicted) | | form | Solid | | color | Light yellow to yellow |
| | 4-(4-Benzhydryl-1-piperazinyl)-1-methyl-3-nitroquinolin-2(1H)-one Usage And Synthesis |
| Uses | BMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes[1]. | | References | [1] Michael Wichroski, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023 Oct 25;15(719):eadh1892. DOI:10.1126/scitranslmed.adh1892 |
| | 4-(4-Benzhydryl-1-piperazinyl)-1-methyl-3-nitroquinolin-2(1H)-one Preparation Products And Raw materials |
|
|
Tag:4-(4-Benzhydryl-1-piperazinyl)-1-methyl-3-nitroquinolin-2(1H)-one(313552-29-3)
Related Product Information
|
|
COCHLIOQUINONE A
Anti-cancer compound library
1,5-Naphthyridine-2-carbonitrile, 5,6-dihydro-3-(2-hydroxyethoxy)-5-methyl-8-[4-(5-methyl-2-benzoxazolyl)-1-piperidinyl]-6-oxo-
1H-[1,2,4]Triazolo[3,4-b]purine-1-ethanamine, 4-[(2S,5R)-4-[bis(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-N,N-dimethyl-
8-[(2S,5R)-4-[Bis(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile
1,5-Naphthyridine-2-carbonitrile, 8-[(2S,5R)-4-[bis(4-chlorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-5,6-dihydro-5-methyl-6-oxo-
|